These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 20533477)

  • 1. The engineering of an orally active conotoxin for the treatment of neuropathic pain.
    Clark RJ; Jensen J; Nevin ST; Callaghan BP; Adams DJ; Craik DJ
    Angew Chem Int Ed Engl; 2010 Sep; 49(37):6545-8. PubMed ID: 20533477
    [No Abstract]   [Full Text] [Related]  

  • 2. Synthesis and SAR of 4-aminocyclopentapyrrolidines as orally active N-type calcium channel inhibitors for inflammatory and neuropathic pain.
    Beebe X; Yeung CM; Darczak D; Shekhar S; Vortherms TA; Miller L; Milicic I; Swensen AM; Zhu CZ; Banfor P; Wetter JM; Marsh KC; Jarvis MF; Scott VE; Schrimpf MR; Lee CH
    Bioorg Med Chem Lett; 2013 Sep; 23(17):4857-61. PubMed ID: 23876987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel series of pyrazolylpiperidine N-type calcium channel blockers.
    Subasinghe NL; Wall MJ; Winters MP; Qin N; Lubin ML; Finley MF; Brandt MR; Neeper MP; Schneider CR; Colburn RW; Flores CM; Sui Z
    Bioorg Med Chem Lett; 2012 Jun; 22(12):4080-3. PubMed ID: 22608964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The chemical synthesis of α-conotoxins and structurally modified analogs with enhanced biological stability.
    Banerjee J; Gyanda R; Chang YP; Armishaw CJ
    Methods Mol Biol; 2013; 1081():13-34. PubMed ID: 24014431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting voltage-gated calcium channels: developments in peptide and small-molecule inhibitors for the treatment of neuropathic pain.
    Vink S; Alewood PF
    Br J Pharmacol; 2012 Nov; 167(5):970-89. PubMed ID: 22725651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analgesic (omega)-conotoxins CVIE and CVIF selectively and voltage-dependently block recombinant and native N-type calcium channels.
    Berecki G; Motin L; Haythornthwaite A; Vink S; Bansal P; Drinkwater R; Wang CI; Moretta M; Lewis RJ; Alewood PF; Christie MJ; Adams DJ
    Mol Pharmacol; 2010 Feb; 77(2):139-48. PubMed ID: 19892914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small molecules targeting sodium and calcium channels for neuropathic pain.
    Bear B; Asgian J; Termin A; Zimmermann N
    Curr Opin Drug Discov Devel; 2009 Jul; 12(4):543-61. PubMed ID: 19562650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Solution structure of omega-conotoxin MVIIC, a high affinity ligand of P-type calcium channels, using 1H NMR spectroscopy and complete relaxation matrix analysis.
    Farr-Jones S; Miljanich GP; Nadasdi L; Ramachandran J; Basus VJ
    J Mol Biol; 1995 Apr; 248(1):106-24. PubMed ID: 7731037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conotoxins containing nonnatural backbone spacers: cladistic-based design, chemical synthesis, and improved analgesic activity.
    Green BR; Catlin P; Zhang MM; Fiedler B; Bayudan W; Morrison A; Norton RS; Smith BJ; Yoshikami D; Olivera BM; Bulaj G
    Chem Biol; 2007 Apr; 14(4):399-407. PubMed ID: 17462575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-allodynic efficacy of the chi-conopeptide, Xen2174, in rats with neuropathic pain.
    Nielsen CK; Lewis RJ; Alewood D; Drinkwater R; Palant E; Patterson M; Yaksh TL; McCumber D; Smith MT
    Pain; 2005 Nov; 118(1-2):112-24. PubMed ID: 16154696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drugs from the sea: conotoxins as drug leads for neuropathic pain and other neurological conditions.
    Alonso D; Khalil Z; Satkunanthan N; Livett BG
    Mini Rev Med Chem; 2003 Nov; 3(7):785-7. PubMed ID: 14529519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T-type calcium channel blockers: spiro-piperidine azetidines and azetidinones-optimization, design and synthesis.
    Smith EM; Sorota S; Kim HM; McKittrick BA; Nechuta TL; Bennett C; Knutson C; Burnett DA; Kieselgof J; Tan Z; Rindgen D; Bridal T; Zhou X; Jia YP; Dong Z; Mullins D; Zhang X; Priestley T; Correll CC; Tulshian D; Czarniecki M; Greenlee WJ
    Bioorg Med Chem Lett; 2010 Aug; 20(15):4602-6. PubMed ID: 20580233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pyrazolopyridazine alpha-2-delta-1 ligands for the treatment of neuropathic pain.
    Myatt JW; Healy MP; Bravi GS; Billinton A; Johnson CN; Matthews KL; Jandu KS; Meng W; Hersey A; Livermore DG; Douault CB; Witherington J; Bit RA; Rowedder JE; Brown JD; Clayton NM
    Bioorg Med Chem Lett; 2010 Aug; 20(15):4683-8. PubMed ID: 20566291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The synthesis of SO-3, a conopeptide with high analgesic activity derived from Conus striatus.
    Dai Q; Liu F; Zhou Y; Lu B; Yu F; Huang P
    J Nat Prod; 2003 Sep; 66(9):1276-9. PubMed ID: 14510617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-activity relationships of omega-conotoxins at N-type voltage-sensitive calcium channels.
    Nielsen KJ; Schroeder T; Lewis R
    J Mol Recognit; 2000; 13(2):55-70. PubMed ID: 10822250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and biological characterization of a series of analogues of omega-conotoxin GVIA.
    Flinn JP; Murphy R; Boublik JH; Lew MJ; Wright CE; Angus JA
    J Pept Sci; 1995; 1(6):379-84. PubMed ID: 9223017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic potential of conopeptides.
    Schroeder CI; Craik DJ
    Future Med Chem; 2012 Jun; 4(10):1243-55. PubMed ID: 22800369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-activity relationships of diphenylpiperazine N-type calcium channel inhibitors.
    Pajouhesh H; Feng ZP; Ding Y; Zhang L; Pajouhesh H; Morrison JL; Belardetti F; Tringham E; Simonson E; Vanderah TW; Porreca F; Zamponi GW; Mitscher LA; Snutch TP
    Bioorg Med Chem Lett; 2010 Feb; 20(4):1378-83. PubMed ID: 20117000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure and activity of (2,8)-dicarba-(3,12)-cystino alpha-ImI, an alpha-conotoxin containing a nonreducible cystine analogue.
    MacRaild CA; Illesinghe J; van Lierop BJ; Townsend AL; Chebib M; Livett BG; Robinson AJ; Norton RS
    J Med Chem; 2009 Feb; 52(3):755-62. PubMed ID: 19125616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of basic residues for the binding of omega-conotoxin GVIA to N-type calcium channels.
    Sato K; Park NG; Kohno T; Maeda T; Kim JI; Kato R; Takahashi M
    Biochem Biophys Res Commun; 1993 Aug; 194(3):1292-6. PubMed ID: 8394704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.